Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review |
| |
| Authors: | Yuki Yoshimatsu Noriyuki Ebi Ryunosuke Ooi Takuto Sueyasu Saori Nishizawa Miyuki Munechika Kohei Yoshimine Yuki Ko Hiromi Ide Kosuke Tsuruno Kazunori Tobino |
| |
| Affiliation: | 1.Department of Respiratory Medicine, Iizuka Hospital, Japan; 2.Department of Physiology, Hyogo College of Medicine, Japan; 3.Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan |
| |
| Abstract: | ![]()
The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients. |
| |
| Keywords: | epidermal growth factor receptor EGFR tyrosine kinase inhibitor TKI adenosquamous rechallenge |
|
